KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 628 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Plain language summary of PAPILLON: amivantamab plus chemotherapy in untreated EGFR-mutated non-small-cell lung cancer. PMID 39012623 · Future Oncol · 2024 The provided record is a plain language summary without an abstract or full text, and no signals for time-to-event endpoints (OS, PFS, DFS, EFS, RFS, TTP, KM curves, or HR) are present. While it appears oncology and drug-related, the lack of clear human trial, randomized design, phase, and primary result data prevents eligibility.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
The efficacy of coaxial percutaneous iodine-125 seed implantation combined with arterial infusion chemotherapy for advanced pancreatic cancer: a randomized clinical trial. PMID 38687687 · Int J Radiat Biol · 2024 The record describes a randomized clinical trial in advanced pancreatic cancer with a drug-containing intervention (arterial infusion chemotherapy) and a primary time-to-event efficacy endpoint (survival time). However, the trial phase is not explicitly stated in the provided metadata as Phase III/IIIb or Phase II/III, and it cannot be inferred from the drug name or other available information. Therefore, eligibility cannot be confirmed.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Patient-Controlled Subcutaneous Analgesia with Hydromorphone versus Oral Oxycontin for Opioid Titration of Cancer Pain: A Prospective Multicenter Randomized Trial. PMID 38628430 · J Pain Res · 2024 The study is a randomized trial comparing two analgesic regimens for cancer pain titration. While it involves human cancer patients and drug interventions, the primary endpoint (time to successful titration) is a pain management outcome, not a standard oncology time-to-event efficacy endpoint like OS, PFS, or DFS. Therefore, it does not meet the criteria for inclusion in an oncology Kaplan-Meier digitization cohort focusing on treatment efficacy.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Plain language summary of the TRANSFORM study primary analysis results: liso-cell as a second treatment regimen for large B-cell lymphoma following failure of the first treatment regimen. PMID 38547003 · Future Oncol · 2024 The record is a patient education handout about the TRANSFORM study, not a primary formal clinical trial result report. While the topic is oncological and involves a human drug intervention, the publication type, lack of explicit time-to-event endpoint reporting in the provided metadata, and absence of confirmed randomization and phase details prevent eligibility.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Development and testing of a random forest-based machine learning model for predicting events among breast cancer patients with a poor response to neoadjuvant chemotherapy. PMID 37777809 · Eur J Med Res · 2023-Sep-30 The record describes a machine learning model development study for predicting events in breast cancer patients after neoadjuvant chemotherapy, not a randomized clinical trial report. Although it is tagged as a 'Randomized Controlled Trial' in publication types, this refers to the random split of data for model training/testing, not a trial comparing drug interventions. There is no time-to-event efficacy endpoint (OS, PFS, etc.) and it is not a Phase III or definitive trial report.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Tamoxifen-predictive value of gene expression signatures in premenopausal breast cancer: data from the randomized SBII:2 trial. PMID 37773134 · Breast Cancer Res · 2023-Sep-29 The record is a secondary, biomarker-focused analysis of a randomized trial. While the trial itself may be a definitive phase, the abstract does not establish the phase, and the analysis is not a primary efficacy report of the trial.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Correction: Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study. PMID 37752114 · Blood Cancer J · 2023-Sep-27 The record clearly describes an updated report from a randomized Phase 3 drug trial in human oncology. However, the abstract is missing, and no explicit signal for a time-to-event efficacy endpoint (like OS/PFS with KM/HR) is present in the provided title or metadata. Therefore, eligibility cannot be established with certainty.
H B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of Infliximab in Intestinal Behçet's Disease: A Multicenter, Phase 3 Study (BEGIN). PMID 36578194 · Gut Liver · 2023-Sep-15 The study is a Phase 3, open-label, single-arm trial of infliximab for intestinal Behçet's disease, which is not a malignant neoplasm. It lacks a randomized design and does not report a time-to-event efficacy endpoint (e.g., OS, PFS, DFS) or use Kaplan-Meier/HR analysis for such an endpoint.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Radiotherapy versus low-dose tamoxifen following breast-conserving surgery for low-risk and estrogen receptor-positive breast ductal carcinoma in situ: an international open-label randomized non-inferiority trial (TBCC-ARO DCIS Trial). PMID 37710198 · BMC Cancer · 2023-Sep-14 The record describes a protocol for a randomized trial with oncology, human, randomized, and time-to-event criteria met. It includes a drug intervention (tamoxifen). However, it is a protocol (ClinicalTrials.gov ID: NCT04046159) and does not report formal trial results. Additionally, the trial phase is not explicitly stated as Phase III, IIIb, or II/III in the provided metadata, making that criterion unclear. Therefore, it is not eligible as an original formal-result report.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Colorectal Cancer Screening Decision Based on Predicted Risk: Protocol for a Pilot Randomized Controlled Trial. PMID 37676720 · JMIR Res Protoc · 2023-Sep-07 The record is a protocol for a pilot randomized controlled trial on colorectal cancer screening. It is not a Phase III/IIIb or Phase II/III randomized trial with results. The intervention compares personalized risk communication and screening recommendations versus usual care, not a drug intervention. The primary outcome is screening uptake (a process measure), not a time-to-event efficacy endpoint like OS or PFS. Therefore, it does not meet the eligibility criteria for the KM digitization cohort.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Erratum: Randomized Phase III Trial Evaluating Subcutaneous Rituximab for the First-Line Treatment of Low-Tumor Burden Follicular Lymphoma: Results of a LYSA Study. PMID 37450783 · J Clin Oncol · 2023-Sep-01 The record is a published erratum, not an original formal result report. While the title describes a randomized Phase III drug trial in oncology, the erratum publication type and lack of abstract content prevent confirmation of a primary/key secondary time-to-event efficacy endpoint. Metadata cannot establish human subject data.
H B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Summary of Research: Adjuvant Nivolumab Plus Ipilimumab Versus Placebo for Localized Renal Cell Carcinoma After Nephrectomy (CheckMate 914): A Double-Blind, Randomized, Phase 3 Trial. PMID 37659025 · Target Oncol · 2023-Sep Cannot confirm time-to-event endpoint from provided text. Abstract mentions 'risk of RCC returning or death' which could imply DFS or OS, but the specific endpoint (e.g., DFS, OS) and statistical methods (e.g., Kaplan-Meier, HR) are not explicitly stated. Therefore, time_to_event criterion is uncertain.
H L S B
旧组与严格 v3 交集 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Tumour stage, treatment, and survival of women with high-grade serous tubo-ovarian cancer in UKCTOCS: an exploratory analysis of a randomised controlled trial. PMID 37657461 · Lancet Oncol · 2023-Sep The study is an exploratory analysis of a large, randomized ovarian cancer screening trial. It is oncology and human, and randomized. However, it is not a Phase III therapeutic trial of a drug intervention; the primary intervention is screening. The survival analysis is presented for a subgroup of patients with high-grade serous cancer and is not the primary/key secondary endpoint of a Phase III drug trial. Therefore, it does not meet the criteria for a drug-containing Phase III randomized trial with a primary/key secondary time-to-event efficacy endpoint.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Intravenous versus super-selected intra-arterial chemotherapy in children with advanced unilateral retinoblastoma: an open-label, multicentre, randomised trial. PMID 37536351 · Lancet Child Adolesc Health · 2023-Sep The trial meets criteria for oncology, human, randomized, time-to-event endpoint, drug intervention, and original result. However, the trial phase is not explicitly reported in the provided text. The metadata 'deterministic_review' notes that phase is not confirmed and requires review. Since the phase cannot be established from the provided evidence, the 'phase3_or_definitive' criterion is null, making the record ineligible.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Correction: Three-year survival and distribution of lymph node metastases in gastric cancer following neoadjuvant chemotherapy: results from a European randomized clinical trial. PMID 37516694 · Surg Endosc · 2023-Sep The record is a 'Published Erratum', which is not a primary report of trial results. The title mentions a 'European randomized clinical trial' and 'survival', suggesting oncology, human, randomized, and drug intervention. However, without the abstract or full text, the phase (III/IIIb or II/III), the primary/key secondary time-to-event endpoint, and whether it is an original result cannot be confirmed. The erratum likely modifies a previous publication, but the original report's status is unknown.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Preoperative chemotherapy prior to primary tumour resection for asymptomatic synchronous unresectable colorectal liver-limited metastases: The RECUT multicenter randomised controlled trial. PMID 37473466 · Eur J Cancer · 2023-Sep The record is eligible on all criteria except the trial phase, which is not explicitly stated in the provided metadata (e.g., as 'Phase III' or 'Phase II/III'). The deterministic review correctly flags this as 'phase3_evidence_unclear'. Therefore, is_eligible is set to null. Confidence is moderate as all other criteria are met.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Pembrolizumab plus chemotherapy for advanced non-small-cell lung cancer without tumor PD-L1 expression in Asia. PMID 37465924 · Immunotherapy · 2023-Sep Cannot confirm that the pooled analysis represents the original formal result report of a Phase III/IIIb or Phase II/III trial. The abstract states data are pooled from three studies but does not specify their individual phases or confirm that this pooled analysis is the primary/definitive report for any single trial.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
General anesthesia combined with bilateral 2-level erector spinae plane block may accelerate postoperative gastrointestinal function recovery and rehabilitation process in patients undergoing posterior lumbar surgery: A randomized controlled trial. PMID 37429768 · Surgery · 2023-Sep The study is a randomized controlled trial in humans, but it is not oncology-focused, does not involve a drug intervention as the primary treatment, and does not use a standard oncology time-to-event efficacy endpoint.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Efficacy of mindfulness-based relapse prevention in a sample of veterans in a substance use disorder aftercare program: A randomized controlled trial. PMID 37364669 · J Subst Use Addict Treat · 2023-Sep The study is a randomized controlled trial of a mindfulness-based intervention for substance use disorder in veterans. It does not involve human malignant neoplasms (cancer), does not test a drug-containing intervention, and does not report a time-to-event efficacy endpoint (OS, PFS, DFS, etc.) with Kaplan-Meier or HR analysis. The MeSH term 'Neoplasm Recurrence, Local' appears to be an indexing error unrelated to the study's actual focus on substance use relapse.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
TP53 Gain-of-Function Mutation is a Poor Prognostic Factor in High-Methylated Metastatic Colorectal Cancer. PMID 37355363 · Clin Colorectal Cancer · 2023-Sep The record describes a subgroup analysis of biomarkers from a Phase III randomized trial, but it does not report on a drug-containing intervention as the primary focus, making it ineligible under the cohort criteria which require a drug intervention.
H L S B
旧组与严格 v3 交集 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Adjuvant hepatic artery infusion pump chemotherapy for resected colorectal cancer liver metastases. PMID 37321884 · Surgery · 2023-Sep The record is a review or commentary, not an original formal-result report of a single randomized trial. It discusses multiple trials but does not present primary data from one specific Phase III/IIIb or Phase II/III trial.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Conditional survival does not improve over time in metastatic castration-resistant prostate cancer patients undergoing docetaxel. PMID 37290911 · Prostate · 2023-Sep The record is a pooled, secondary analysis of multiple trials, not the primary, formal-result report of a single Phase III/IIIb or Phase II/III randomized trial. While the constituent trials likely included a drug intervention (docetaxel) and reported time-to-event data, this specific publication does not present the original trial results required for eligibility.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Reduced prescription of TNF-inhibitors in chronic arthritis based on therapeutic drug monitoring: A randomized controlled trial. PMID 36315419 · Scand J Rheumatol · 2023-Sep The study is a randomized controlled trial with drug intervention (TNF-inhibitors) and primary results, but it is not an oncology study and lacks a time-to-event efficacy endpoint.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Construction of web-based prediction nomogram models for cancer-specific survival in patients at stage IV of hepatocellular carcinoma depending on SEER database. PMID 38432884 · Zhong Nan Da Xue Xue Bao Yi Xue Ban · 2023-Oct-28 The record describes a prognostic nomogram construction study using a retrospective database (SEER), not a report of a randomized Phase III clinical trial. While it involves oncology, humans, and mentions chemotherapy as a prognostic factor, it does not meet the core criteria of being a formal result report from a Phase III/IIIb or Phase II/III randomized drug trial with a primary/key secondary time-to-event efficacy endpoint (OS, PFS, etc.) for comparing drug interventions. The 'Randomized Controlled Trial' publication type is likely a misclassification, as the study involves random splitting of a retrospective cohort into training/validation sets, not randomization of patients to different drug interventions.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
FOVOCIP study: a multicenter randomized trial of fosfomycin versus ciprofloxacin for febrile neutropenia in hematologic patients-efficacy and microbiologic safety. PMID 37891616 · Trials · 2023-Oct-27 While the record is an oncology Phase III randomized drug trial, it is a protocol summary without reported time-to-event results. The abstract describes a non-inferiority trial for febrile neutropenia prevention, but does not mention or provide Kaplan-Meier curves, hazard ratios, or any time-to-event endpoint (OS, PFS, etc.). The study appears to be ongoing or in planning, lacking primary efficacy data.
H L S B
旧组与严格 v3 交集 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
More intensive therapy as more effective treatment for frail patients with multiple myeloma [corrected]. PMID 37582048 · Blood Adv · 2023-Oct-24 The record describes a randomized analysis comparing VRd vs Rd for multiple myeloma, reporting overall survival hazard ratios, and is classified as a randomized controlled trial in publication types. However, the explicit phase (e.g., Phase III) is not confirmed in the provided metadata (title, abstract, or publication types), so the phase criterion cannot be definitively established.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Nonrestrictive diet does not increase infections during post-HSCT neutropenia: data from a multicenter randomized trial. PMID 37450382 · Blood Adv · 2023-Oct-10 The trial is randomized, oncology-related, and reports original results. However, it fails the primary criterion of having a time-to-event efficacy endpoint (e.g., OS, PFS, DFS) as the primary or key secondary outcome; the primary endpoint is infection incidence (a binary outcome), not a survival or progression-free time-to-event analysis. The phase is not specified as Phase III/IIIb or II/III. Therefore, it is not eligible for the KM digitization cohort.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Busulfan Plus Fludarabine Compared With Busulfan Plus Cyclophosphamide for AML Undergoing HLA-Haploidentical Hematopoietic Cell Transplantation: A Multicenter Randomized Phase III Trial. PMID 37335960 · J Clin Oncol · 2023-Oct-10 The study meets most criteria: it is an oncology randomized Phase III trial with drug interventions and reports time-to-event outcomes with HRs. However, the primary endpoint is transplant-related mortality (TRM), which is a safety/toxicity endpoint, not a standard oncology efficacy endpoint. The trial's purpose is to compare conditioning regimens for stem cell transplantation, not to evaluate a systemic anticancer drug's efficacy. Therefore, it does not fit the cohort's focus on oncology drug efficacy trials.
H L S B
旧组与严格 v3 交集 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Relugolix vs. Leuprolide Effects on Castration Resistance-Free Survival from the Phase 3 HERO Study in Men with Advanced Prostate Cancer. PMID 37835548 · Cancers (Basel) · 2023-Oct-05 This is a Phase 3 randomized controlled trial in oncology (advanced prostate cancer) comparing a drug (relugolix) to an active comparator (leuprolide). It reports a formal secondary time-to-event efficacy endpoint (castration resistance-free survival) with hazard ratio and Kaplan-Meier-derived rates. It is an original result published as a journal article, meeting all required criteria.
H S B
严格 v3 独有 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Left Ventricular Ejection Fraction in Patients With Ovarian Cancer Treated With Avelumab, Pegylated Liposomal Doxorubicin, or Both. PMID 37665777 · Oncologist · 2023-Oct-03 The report is from a Phase III randomized trial but focuses exclusively on cardiac safety (LVEF and cardiac AEs). It does not present or include a primary or key secondary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR).
H L B
旧查询独有 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Correction: A phase III, multicenter, randomized study of olvimulogene nanivacirepvec followed by platinum-doublet chemotherapy and bevacizumab compared with platinum-doublet chemotherapy and bevacizumab in women with platinum-resistant/refractory ovarian cancer. PMID 37783482 · Int J Gynecol Cancer · 2023-Oct-02 Title indicates Phase III randomized trial with drug intervention in oncology (ovarian cancer). However, abstract is empty, so cannot establish human subjects, time-to-event endpoint (OS/PFS/etc.), or that this is a primary result report (vs. correction/erratum).
H B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Revisiting the predictive role of 18F-fluorodeoxyglucose positron emission tomography/computerized tomography on treatment outcome in early-stage favorable Hodgkin lymphoma. PMID 37805963 · Hematol Oncol · 2023-Oct The abstract describes commentary on three large, phase III, randomized trials and preliminary results from an ongoing phase 2 study (RAFTING). No specific time-to-event efficacy endpoints (e.g., OS, PFS) or corresponding Kaplan-Meier/HR results are reported. The publication is a commentary/article summarizing trials, not an original formal result report of a single trial.
H B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Association between local treatment modalities and event-free survival, overall survival, and local recurrence in patients with localised Ewing Sarcoma. Report from the Ewing 2008 trial. PMID 37595489 · Eur J Cancer · 2023-Oct The study is a randomized oncology trial with time-to-event endpoints and a drug intervention (chemotherapy). However, the explicit trial phase (Phase III/IIIb or Phase II/III) is not confirmed in the provided record, which is a required criterion for eligibility. Metadata signals indicate 'phase3: false'. Therefore, eligibility cannot be definitively established.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Correction: A Multicenter Survey on Eligibility for a Randomized Phase III Trial of Adjuvant Chemotherapy for Resected Biliary Tract Cancer (JCOG1202, ASCOT). PMID 37505358 · Ann Surg Oncol · 2023-Oct The record is a correction/erratum for a trial, not an original result report. The empty abstract prevents verification of required criteria like human study and time-to-event endpoint. Therefore, eligibility cannot be established.
H B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Feasibility study on individualized management of postoperative patients with differentiated thyroid cancer based on internet and programming technology. PMID 37438541 · J Cancer Res Clin Oncol · 2023-Oct The study is a randomized feasibility study in differentiated thyroid cancer, but it is not a Phase III/IIIb or Phase II/III trial, the experimental intervention is a management mode (mobile app), not a drug intervention, and the primary endpoint is not a time-to-event efficacy endpoint like OS/PFS/DFS etc.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
The clinical effect of modified slow Mohs circular skin biopsy on penoscrotal extramammary Paget's disease. PMID 36737341 · Asian J Surg · 2023-Oct The study is a randomized trial in human oncology but is ineligible because it lacks a drug intervention and does not report a time-to-event efficacy endpoint. It is a surgical technique comparison.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Quality assurance in a phase III, multicenter, randomized trial of POstmastectomy radioThErapy in Node posiTive breast cancer with or without Internal mAmmary nodaL irradiation (POTENTIAL): a planning benchmark case. PMID 38031125 · Radiat Oncol · 2023-Nov-29 This is a planning benchmark case report for a phase III randomized trial evaluating radiotherapy (internal mammary nodal irradiation) in breast cancer. It reports on radiation plan quality and protocol compliance, not on a time-to-event efficacy endpoint like OS or PFS. While it is from a randomized, phase III oncology trial, it lacks a drug-containing intervention and a primary time-to-event efficacy endpoint, making it ineligible.
H L B
旧查询独有 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Life quality improvement of patients with non-small cell lung cancer undergoing targeted therapy: A case study of continuous care. PMID 37932985 · Medicine (Baltimore) · 2023-Nov-03 The study is a randomized controlled trial in oncology with time-to-event endpoints and a drug intervention. However, the primary focus and reported outcome is on life quality improvement (QoL scales, compliance, adverse reactions), making the report type 'quality_of_life'. The primary efficacy endpoint is not the focus; thus, it does not meet the requirement for a primary/key time-to-event efficacy endpoint report. Additionally, the trial phase is not explicitly stated as Phase III/IIIb or Phase II/III.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Homoharringtonine-Based Induction Regimen Improved the Remission Rate and Survival Rate in Chinese Childhood AML: A Report From the CCLG-AML 2015 Protocol Study. PMID 37531592 · J Clin Oncol · 2023-Nov-01 The record is an original result of a randomized drug trial with oncology, human, and time-to-event endpoints. However, the explicit Phase III/IIIb or Phase II/III designation is not clearly established in the provided metadata or abstract. The trial is described as a 'protocol study' and uses a '2015 Protocol,' but the phase is not explicitly stated as Phase III. Therefore, the phase criterion cannot be definitively established.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Clinical Effect of the Combination of Compound Kushen Injection and Gemcitabine on Postoperative Patients with Non-Muscle Invasive Bladder Cancer and Its Influence on Serum-Related Factors. PMID 38053420 · Arch Esp Urol · 2023-Nov The study is a randomized controlled trial in oncology with a drug intervention and reports original results. However, the phase is not explicitly stated in the provided metadata (phase3_or_definitive: null), and the primary/time-to-event endpoint is not identified; outcomes reported are serum-related factors, immune function, recurrence rate, and safety, not OS/PFS/DFS/etc. with Kaplan-Meier or HR. Therefore, it does not meet the requirement for a time-to-event efficacy endpoint.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Shallow whole genome sequencing approach to detect Homologous Recombination Deficiency in the PAOLA-1/ENGOT-OV25 phase-III trial. PMID 37945748 · Oncogene · 2023-Nov The record describes a secondary analysis validating a new biomarker test using existing trial data, not an original formal-result report of the randomized trial's efficacy endpoint.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Pharmacokinetics and Pharmacodynamics of Burixafor Hydrobromide (GPC-100), a Novel C-X-C Chemokine Receptor 4 Antagonist and Mobilizer of Hematopoietic Stem/Progenitor Cells, in Mice and Healthy Subjects. PMID 37539772 · Clin Pharmacol Drug Dev · 2023-Nov The study is a Phase I, randomized, controlled trial in healthy volunteers evaluating the pharmacokinetics, pharmacodynamics, and safety of burixafor for hematopoietic stem cell mobilization. It is not a cancer treatment trial, does not report a Phase III or definitive trial phase, and lacks any primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS). Therefore, it is ineligible.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
A prognostic model for predicting progression-free survival in patients with advanced non-small cell lung cancer after image-guided microwave ablation plus chemotherapy. PMID 37318606 · Eur Radiol · 2023-Nov The study is a secondary analysis (prognostic model development) using data from a prior RCT, not a formal primary result report of a definitive phase trial. The phase of the underlying trial is not explicitly confirmed as Phase III/IIIb or Phase II/III in the metadata.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Relationship Between Baseline Prostate-specific Antigen on Cancer Detection and Prostate Cancer Death: Long-term Follow-up from the European Randomized Study of Screening for Prostate Cancer. PMID 37088597 · Eur Urol · 2023-Nov The record describes a randomized screening trial (ERSPC) analyzing prostate-specific antigen (PSA) levels and prostate cancer mortality. It is a human oncology randomized controlled trial with long-term follow-up. However, it fails key eligibility criteria: 1) There is no drug-containing intervention (screening with PSA testing is not a drug intervention); 2) The phase is not explicitly stated as Phase III or equivalent; 3) While prostate cancer-specific mortality is a time-to-event outcome, the trial does not evaluate a drug therapy's effect on this endpoint, which is required for the cohort.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
HELP - Heidelberg decision aid for lung cancer patients: a randomized controlled clinical trial. PMID 37231417 · Trials · 2023-May-25 The record describes a protocol for a randomized trial evaluating a decision aid intervention for lung cancer patients. It lacks a drug-containing intervention and a time-to-event efficacy endpoint (OS, PFS, etc.), and presents no results. Therefore, it does not meet the eligibility criteria.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Drainless robot-assisted minimally invasive oesophagectomy-randomized controlled trial (RESPECT). PMID 37127683 · Trials · 2023-May-02 The record is a protocol for a randomized trial on surgical drain management in oesophageal cancer surgery. It lacks results and does not report a time-to-event endpoint (like OS/PFS) or a drug intervention. It is therefore excluded.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Incidence of Primary End Point Changes Among Active Cancer Phase 3 Randomized Clinical Trials. PMID 37195664 · JAMA Netw Open · 2023-May-01 The record is a meta-research cross-sectional study assessing changes in primary endpoints across many oncology RCTs. It does not present original results, including time-to-event efficacy data or hazard ratios, for a single drug-containing randomized trial.
H L B
旧查询独有 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Risk and location of distant metastases in patients with locally advanced rectal cancer after total neoadjuvant treatment or chemoradiotherapy in the RAPIDO trial. PMID 36996624 · Eur J Cancer · 2023-May All required criteria are explicitly met except the trial phase. The metadata does not confirm Phase III/IIIb or Phase II/III status. The study is a randomized trial with a drug intervention and primary time-to-event efficacy results, but the phase is not established in the provided record.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Using Oncotype DX breast recurrence score® assay to define the role of neoadjuvant endocrine therapy in early-stage hormone receptor-positive breast cancer. PMID 36897465 · Breast Cancer Res Treat · 2023-May The record describes a secondary pooled analysis of randomized data, but the primary efficacy endpoints are pathologic response rates (pCR/cCR), not time-to-event outcomes like OS or PFS. The phase of the underlying trials is also not definitively established as Phase III/IIIb or Phase II/III from the provided metadata.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Disease-free Survival Analysis for Patients with High-risk Muscle-invasive Urothelial Carcinoma from the Randomized CheckMate 274 Trial by PD-L1 Combined Positive Score and Tumor Cell Score. PMID 36868932 · Eur Urol · 2023-May The record is eligible as it reports a formal result from a randomized Phase III oncology trial with a drug intervention and a time-to-event efficacy endpoint. The analysis is a pre-specified biomarker subgroup analysis within the trial's results, not a post-hoc or biomarker-only study.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -